Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-25-045098
Filing Date
2025-05-19
Accepted
2025-05-19 08:30:31
Documents
14
Period of Report
2023-12-11
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 TO FORM 8-K ea0242647-8ka5_aditxt.htm   iXBRL 8-K/A 35511
2 UNAUDITED FINANCIAL STATEMENTS OF EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES AS O ea024264701ex99-1_aditxt.htm EX-99.1 596249
3 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE THREE MO ea024264701ex99-2_aditxt.htm EX-99.2 142362
  Complete submission text file 0001213900-25-045098.txt   1060137

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adtx-20231211.xsd EX-101.SCH 3008
5 XBRL LABEL FILE adtx-20231211_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE adtx-20231211_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0242647-8ka5_aditxt_htm.xml XML 5332
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39336 | Film No.: 25961582
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)